Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-26-075781
Filing Date
2026-07-07
Accepted
2026-07-07 09:18:33
Documents
13
Period of Report
2026-06-30
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0297249-8ka1_ostherapies.htm   iXBRL 8-K/A 39609
2 SIDE LETTER, DATED JUNE 30, 2026, BETWEEN OS THERAPIES INCORPORATED AND LEONITE ea029724901ex10-3.htm EX-10.3 14466
3 GRAPHIC ea029724901_ex10-3img1.jpg GRAPHIC 5793
  Complete submission text file 0001213900-26-075781.txt   237654

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ostx-20260630.xsd EX-101.SCH 3023
5 XBRL LABEL FILE ostx-20260630_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE ostx-20260630_pre.xml EX-101.PRE 22364
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0297249-8ka1_ostherapies_htm.xml XML 4300
Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

EIN.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-42195 | Film No.: 261157987
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)